Evaluation of a Hypertonic Seawater Aerosol Therapy Solution in Adults and Children

Inclusion Criteria:

1. Adult subject voluntarily given informed consent to investigation participation inwriting encompassing consent to data recording and verification procedures.

2. Minor subjects (7-17 years old) given informed assent to investigation participationin writing encompassing consent to data recording and verification procedures

3. Male and female subjects, aged from 2 years old;

4. Subject diagnosed with URTIs such as rhinopharyngitis, rhinitis, acuterhinosinusitis or cold based on the medical examination done by the doctor.

5. Subject willing to adhere to the requirements of the protocol, includingavailability for follow-up visits

6. Subject who agrees to no use decongestants, corticosteroids, antibiotics,allergen-specific immunotherapy, antihistamines, non-steroidal anti-inflammatorydrugs (NSAIDs), local nasal antiseptics, other nasal saline solutions orirrigations, nasal sprays, nasal creams or gels, systemic analgesics or antipyretics (except paracetamol if needed);

7. Subject who is able to comply with the study requirements, at the Investigator'sappreciation.

8. For minor (<18) subjects, parents/guardians willing and able to sign written consent

9. Subject able and willing to use an internet-enabled device (computer, tablet, orsmartphone) to complete study procedures (online questionnaires) and have regularaccess to a device with internet connectivity (personal or household device) for theduration of the study.

Exclusion Criteria:

1. Person with hypersensitivity to seawater

2. Subject who previously undergone bronchospasm

3. Children under 2 years of age

4. Pregnant and breastfeeding women

5. Onset of URTI symptoms > 48 hours

6. Subject with COVID or flu

7. Subject presenting alarm symptoms (periorbital oedema/erythema, displaced globe,double vision, ophthalmoplegia, reduced visual acuity, severe headache, frontalswelling, signs of sepsis, sign of meningitis, neurological signs) at the day ofinclusion

8. Subject known to have allergy to the components of the masks that is used with theinhalation device;

9. Subject with asthma,

10. Subject presenting infection or pathology of the inferior respiratory tracts;

11. Subject with chronic nasal obstruction (polypes)

12. Subject who used any decongestants, corticosteroids, antibiotics orallergen-specific immunotherapy within 4 weeks prior to inclusion;

13. Subject who used any antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs)or local nasal antiseptics within 7 days prior to inclusion;

14. Subject who used any nasal saline solutions or irrigations, nasal sprays, nasalcreams or gels, systemic analgesics or antipyretics within 24 hours prior toinclusion;

15. Subject with drug or alcohol abuse

16. Subjects who is deprived for their freedom by administrative or legal decision

17. Subject living in a social or sanitary establishment.

18. Subject being in an exclusion period for a previous study or with a current orrecent (<3 months) participation in another investigational study involving a drugor combined device with drug.

19. Other condition preventing the subject to participate the study in theinvestigator's opinion: subject deemed unreliable or incapable of understanding andcomplying with the study assessment or unrealistic expectations of treatment results